Exome sequencing in every pregnancy? Results of trio exome sequencing in structurally normal fetuses
Prenatal Diagnosis · 2025-03 · 45 (3) · 276-286
DOI: 10.1002/pd.6585 ↗Kurz gefasst
Fachartikel in der Zeitschrift Prenatal Diagnosis, online erschienen am 12.05.2024. Verfasst von Michal Levy und 9 weiteren Autor:innen. Beteiligte Einrichtung: The Genetic Institute of Maccabi Health Services, Rehovot, Israel. Hauptthemen laut MEDLINE: Exome Sequencing, Fetus, Prenatal Diagnosis. Die Arbeit wurde bisher 29-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Objective
This study aimed to assess the detection rate of clinically significant results of prenatal exome sequencing (pES) in low‐risk pregnancies and apparently normal fetuses in non‐consanguineous couples.
Methods
A retrospective analysis of pES conducted at a single center from January 2020 to September 2023 was performed. Genetic counseling was provided, and detailed medical histories were obtained. High‐risk pregnancies were excluded due to major ultrasound anomalies, sonographic soft markers, abnormal maternal biochemical screening, or family history suggestive of monogenic diseases as well as cases with pathogenic and likely pathogenic (P/LP) chromosomal microarray results. Exome analysis focused on ∼2100 genes associated with Mendelian genetic disorders. Variant analysis and classification followed the American College of Medical Genetics and Genomics (ACMG) guidelines.
Results
Among 1825 pES conducted, 1020 low‐risk cases revealed 28 fetuses (2.7%) with potentially clinically significant variants indicating known monogenic diseases, primarily de novo dominant variants (64%). Among these 28 cases, 9 fetuses (0.9%) had the potential for severe phenotypes, including shortened lifespan and intellectual disability, and another 12 had the potential for milder phenotypes. Seven cases were reported with variants of uncertain significance (VUS) that, according to the ACMG criteria, leaned toward LP, constituting 0.7% of the entire cohort. Termination of pregnancy was elected in 13 out of 1020 cases (1.2%) in the cohort, including 7/9 in the severe phenotypes group, 2/12 in the milder phenotype group, and 4/7 in the VUS group.
Conclusion
The 2.7% detection rate highlights the significant contribution of pES in low‐risk pregnancies. However, it necessitates rigorous analysis, and comprehensive genetic counseling before and after testing.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- The Genetic Institute of Maccabi Health Services, Rehovot, Israel.
- School of Medicine, Tel Aviv University, Tel Aviv, Israel.
- Raphael Recanati Genetics Institute, Beilinson Hospital, Rabin Medical Center, Petach Tikva, Israel.
- Bioinformatics Unit, Cancer Research Center, Chaim Sheba Medical Center, Tel-Hashomer, Israel.
ORCID-Profile: Michal Levy, Idit Maya
Zitieren
APA
Levy, M., Lifshitz, S., Goldenberg-Fumanov, M., Bazak, L., Goldstein, R. J., Hamiel, U., Berger, R., Lipitz, S., Maya, I., & Shohat, M. (2025). Exome sequencing in every pregnancy? Results of trio exome sequencing in structurally normal fetuses. Prenatal Diagnosis, 45(3), 276-286. https://doi.org/10.1002/pd.6585
Vancouver
Levy M, Lifshitz S, Goldenberg-Fumanov M, Bazak L, Goldstein RJ, Hamiel U, et al. Exome sequencing in every pregnancy? Results of trio exome sequencing in structurally normal fetuses. Prenatal Diagnosis. 2025;45(3):276-286. doi:10.1002/pd.6585
BibTeX
@article{Levy2025,
author = {Levy, Michal and Lifshitz, Shira and Goldenberg-Fumanov, Mirela and Bazak, Lily and Goldstein, Rayna Joy and Hamiel, Uri and Berger, Rachel and Lipitz, Shlomo and Maya, Idit and Shohat, Mordechai},
title = {Exome sequencing in every pregnancy? Results of trio exome sequencing in structurally normal fetuses},
journal = {Prenatal Diagnosis},
year = {2025},
volume = {45},
number = {3},
pages = {276--286},
doi = {10.1002/pd.6585}
}
EUVIMED